中药治疗帕金森病系统评价再评价
该综述再评价纳入11项系统评价(含230项随机对照试验),评估中药治疗帕金森病的方法学与证据质量。结果显示中药辅助治疗可改善UPDRS、Webster量表、PDQ-39、NMSQuest、中医证候积分及PDSS等结局,单用中药与西药无差异,辅助治疗副作用较少。
要点
- 中药辅助治疗可改善帕金森病运动症状、生活质量及非运动症状。
- 中药单用与常规西药疗效无显著差异,证据不足。
- 中药辅助治疗不良反应一般少于或轻于西药组。
核心结论
- 中药辅助治疗对帕金森病患者有支持证据,但方法学缺陷需谨慎对待。
- 中药单用治疗帕金森病的证据不足。
研究设计与样本
- 系统评价再评价,检索6个数据库至2018年9月。
- 纳入11项系统评价,共230项随机对照试验。
主要发现
- 与常规西药相比,中药辅助治疗在改善UPDRS评分、Webster量表评分、PDQ-39、NMSQuest、中医证候积分及PDSS方面显示显著效果。
- 中药单用与常规西药相比,各项结局指标无差异。
- 9项系统评价报告了不良事件,中药辅助治疗组副作用一般少于或轻于西药组。
关键数值与推荐
- AMSTAR方法学质量评分范围为4至9分。
- GRADE证据质量:主要结局中42%为中等质量,54%为高质量。
临床怎么用
- 可考虑将中药作为帕金森病的辅助治疗以改善症状和生活质量。
- 不宜单独使用中药替代常规西药治疗帕金森病。
- 使用中药辅助治疗时需关注其潜在副作用,但一般较西药轻。
局限性
- 纳入的系统评价存在方法学缺陷,证据需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Parkinson's disease (PD) is a high prevalence neurodegenerative disorder without a disease-modifying therapy. Up to now, a number of systematic reviews have been conducted to evaluate efficacy and safety of Chinese herbal Medicine (CHM) for PD patients. Here, we aimed to assess the methodological quality and reporting quality of systematic reviews using an overview, and then synthesize and evaluate the available evidence level of CHM for PD. Six databases were searched from inception to September 2018. The literatures were selected and data were extracted according to prespecified criteria. A Measurement Tool to Assess Systematic Reviews (AMSTAR) was used to evaluate the quality of methodology, and Grading of Recommendations Assessment, Development, and Evaluation (GRADE) to determine the evidence quality of the primary outcome measures. A total of 11 systematic reviews with 230 RCTs of CHM for PD were included. AMSTAR scores of the included reviews were range from 4 to 9. Compared with conventional western medicine (WCM), CHM paratherapy showed significant effect in improving UPDRS score, Webster scale score, PDQ-39, NMSQuest, CHM Syndrome Integral Scale, and PDSS. However, CHM monotherapy showed no difference relative to WCM according to various outcome measures. Adverse events were reported in 9 systematic reviews. The side effect in CHM paratherapy group was generally less than or lighter than that in WCM group. The quality of the evidence of primary outcomes was moderate (42%) to high (54%) according to the GRADE profiler. The present finding supported the use of CHM paratherapy for PD patients but we should treat the evidence cautiously because of the methodological flaws, whereas there is insufficient evidence of CHM monotherapy for PD.
引用
- Jin XC, Zhang L, Wang Y, et al. An Overview of Systematic Reviews of Chinese Herbal Medicine for Parkinson's Disease. Front Pharmacol. 2019. PMID: 30890935. doi:10.3389/fphar.2019.00155
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。